

2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era
Tweetorial #6 References

Tweet 4

Cree BAC, Arnold DL, Chataway J, et al. Secondary progressive multiple sclerosis: new insights. *Neurology*. 2021;97(8):378-388. <https://doi.org/10.1212/wnl.0000000000012323>

Lublin FD. (2014). New multiple sclerosis phenotypic classification. *Eur Neurol*. 2014;72(suppl 1):1-5. <https://doi.org/10.1159/000367614>

Tweet 5

Barzegar M, Najdaghi S, Afshari-Safavi A, Nehzat N, Mirmosayyeb O, Shaygannejad V. Early predictors of conversion to secondary progressive multiple sclerosis. *Mult Scler Relat Disord*. 2021;54:103115. <https://doi.org/10.1016/j.msard.2021.103115>

Cree BAC, Arnold DL, Chataway J, et al. Secondary progressive multiple sclerosis: new insights. *Neurology*. 2021;97(8):378-388. <https://doi.org/10.1212/wnl.0000000000012323>

Tweet 6

Cree BAC, Arnold DL, Chataway J, et al. Secondary progressive multiple sclerosis: new insights. *Neurology*. 2021;97(8):378-388. <https://doi.org/10.1212/wnl.0000000000012323>

Lublin FD. (2014). New multiple sclerosis phenotypic classification. *Eur Neurol*. 2014;72(suppl 1):1-5. <https://doi.org/10.1159/000367614>

Tweet 8

Cree BAC, Arnold DL, Chataway J, et al. Secondary progressive multiple sclerosis: new insights. *Neurology*. 2021;97(8):378-388. <https://doi.org/10.1212/wnl.0000000000012323>

Dekker I, Eijlers AJC, Popescu V. Predicting clinical progression in multiple sclerosis after 6 & 12 years. *Eur J Neurol*. 2019;26(6):893-902. <https://doi.org/10.1111/ene.13904>

Hänninen K, Viitala M, Paavilainen T. Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple Sclerosis. *Front Neurol*. 2021;11:606. <https://doi.org/10.3389/fneur.2020.00606>

Tweet 9

Cree BAC, Arnold DL, Chataway J, et al. Secondary progressive multiple sclerosis: new insights. *Neurology*. 2021;97(8):378-388. <https://doi.org/10.1212/wnl.0000000000012323>

Tweet 10

Cree BAC, Arnold DL, Chataway J, et al. Secondary progressive multiple sclerosis: new insights. *Neurology*. 2021;97(8):378-388. <https://doi.org/10.1212/wnl.0000000000012323>

Tweet 11

Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. *N Engl J Med*. 2010;362(5):416-426. <https://doi.org/10.1056/NEJMoa0902533>

Tweet 12

Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. *Lancet*. 2018;391(10127):1263-1273. [https://doi.org/10.1016/s0140-6736\(18\)30475-6](https://doi.org/10.1016/s0140-6736(18)30475-6)

Tweet 13

Naismith RT, Wolinsky JS, Wundes A, et al. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. *Mult Scler*. 2019;26(13):1729-1739. <https://doi.org/10.1177/1352458519881761>

Naismith RT, Wundes A, Ziemssen T, et al. diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase iii EVOLVE-MS-2 study. *CNS Drugs*. 2020;34(2):185-196. <https://doi.org/10.1007/s40263-020-00700-0>

Tweet 15

Roos I, Leray E, Casey R, et al. Effects of high- & low-efficacy therapy in secondary progressive multiple sclerosis. *Neurology*. 2021;97(9):e869-e880. <https://doi.org/10.1212/wnl.0000000000012354>

Glossary

9HPT, 9-Hole Peg test
AC, acromioclavicular joint
AE, adverse event
BID, twice a day
CDP, confirmed disability progression
CI, confidence interval
CNS, central nervous system
DMF, dimethyl fumarate
DMT, disease-modifying therapy
DRF, diroximel fumarate
EDSS, Expanded Disability Status Scale
GA, glatiramer acetate
Gd, gadolinium
GGISIS, Global GI Symptom and Impact Scale
GI, gastrointestinal
H, hour
HR, hazard ratio
HTN, hypertension
ID, identify
IGISIS, Individual GI Symptoms and Impact Scale
IM, intramuscular
IV, intravenous
m, month
MRI, magnetic resonance imaging
MS, multiple sclerosis

MSFC, Multiple Sclerosis Functional Composite
NfL, neurofilament light
PBO, placebo
Ph, phase
PO, by mouth
PRO, patient reported outcome
Pt(s), patient(s)
Q4W, every four weeks
Q6W, every six weeks
QD, every day
QM, every month
QOL, quality of life
QW, every week
RCT, randomized controlled trial
RMS, relapsing forms of multiple sclerosis
RRMS, relapsing-remitting multiple sclerosis
RR, risk ratio
S1PR, sphingosine-1-phosphate receptor
SC, subcutaneous
SPMS, secondary-progressive multiple sclerosis
T25FW, Timed 25-foot Walk
TIW, three times a week
Tx, treatment
w/, with
WK, week
Y, year